Targeted inactivation of RHO‐ROCK/MLCK‐MLC2 signaling in CT45A1High MSI‐H CRC cells may sensitize outer cancer cells to NK cell killing and enhance the accessibility of inner CT45A1Low cancer cells for NK cells, benefiting cancer immunotherapy in MSI‐H CRC patients (Fig. 6H). The gene discussed is MYL9; the disease is colorectal carcinoma.